affiliate disclosure · We earn affiliate commission on some vendor links. Audits, scores, and rankings are independent — vendors do not pay for placement and do not see drafts. read more →
The 2024 and 2026 Pharmacy Compounding Advisory Committee votes did not close any peptide vendor. They closed the legal compounded telehealth channel — and that closure is what pushed demand toward the research-peptide market in the first place.
Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) as amended by the Drug Quality and Security Act of 2013; the publicly posted minutes from the FDA Pharmacy Compounding Advisory Committee meetings of October 2024 and April 2026; FDA shortage-status determinations for semaglutide and tirzepatide from 2023 through April 2026; and contemporaneous reporting on compounded-GLP-1 telehealth providers (Hims, Ro, Mochi, Henry, Eden) through the shortage-end transitions.
Section 503A is the part of US drug law that lets traditional compounding pharmacies prepare individualized prescriptions for specific patients without going through the full new-drug-application process. It exists because clinical practice sometimes requires formulations that brand-product manufacturers don't make — different strengths, allergen-free versions, alternative delivery formats.
The 503A exemption comes with conditions. Two of them matter for the GLP-1 story:
There is a narrow exception to the second condition: if the brand product is in FDA-confirmed shortage, compounded versions become permissible during the shortage period. This shortage exemption is the door through which compounded semaglutide and tirzepatide entered the legal telehealth channel from 2022 onward.
Brand semaglutide (Wegovy) entered FDA-confirmed shortage in March 2022. Brand tirzepatide (Zepbound, Mounjaro) entered FDA-confirmed shortage in late 2022 and remained there through most of 2024. The shortage exemption under 503A made compounded versions of both compounds legally available — and a category of telehealth provider emerged to use that exemption commercially:
The combined monthly active patient base across this category at peak in 2024 was reportedly in the hundreds of thousands. The legal basis for the entire category was the shortage-exemption door under 503A.
The shortage door closed in two stages, each approximately matching one of the PCAC meeting cycles.
At the October 2024 PCAC meeting, the committee voted to recommend adding tirzepatide to the 503A do-not-compound list. The recommended addition was based on safety and efficacy concerns specific to compounded versions during the shortage period — the PCAC presentation cited dose-mismatch incidents and labeling-quality issues observed across the compounded-tirzepatide market.
The vote did not immediately bind compounding pharmacies. PCAC recommendations require formal FDA action to enter regulatory effect, and that process can take months. But the policy direction was set in October 2024, and the compounding-pharmacy and telehealth provider networks began planning for the wind-down accordingly.
Through late 2024 and into 2025, the FDA-confirmed shortage status for both semaglutide and tirzepatide began to wind down. Brand-product availability stabilized as Eli Lilly and Novo Nordisk completed manufacturing capacity expansions. With brand product available, the shortage-exemption door that had supported compounded versions began closing on the brand-availability side, independent of the PCAC process.
The combined effect: compounded telehealth providers faced two simultaneous pressures. The 503A do-not-compound list was moving toward formal restriction (PCAC track), and the shortage exemption that justified the compounded versions in the first place was being removed (brand-availability track).
At the April 2026 PCAC meeting, the committee reaffirmed the compounding restrictions on the GLP-1 class, extending and formalizing the regulatory direction set in October 2024. The reaffirmation closed the question of whether the October 2024 vote would face reversal under regulatory or political pressure: it did not, and the policy direction is now stable.
The practical effect on the legal compounded-GLP-1 market is severe. The category that existed at peak in 2024 has substantially contracted. Some telehealth providers have pivoted to brand-only prescription pathways (more expensive, slower reimbursement). Some have exited the GLP-1 line entirely. The compounded-tirzepatide category specifically is approaching closure.
The compounding restrictions did not close any research-peptide vendor. The two markets are legally distinct: 503A governs prescription compounding by licensed pharmacies; research-peptide sales are unrelated to 503A and are governed by the FDA's misbranding and unapproved-drug authorities (the FDA Warning Letter track).
But the two markets are demand-linked. The closure of the legal compounded-GLP-1 channel removed a substantial fraction of legal buyer access to GLP-1 compounds without a brand-product prescription. A portion of that displaced demand migrated to the research-peptide channel, which exists in a different legal category but offers overlapping compounds (semaglutide, tirzepatide, retatrutide).
This migration is what made the research-peptide vendor market larger and more visible through 2024–2026. It is also what attracted the increased FDA Warning Letter enforcement in the September 2025 sweep and following actions: as the demand pressure pushed research-peptide vendors toward more aggressive marketing, the FDA's unapproved-drug-claims authority became the active enforcement tool.
The pattern: regulatory pressure on the legal channel produces demand pressure on the adjacent channel; the adjacent channel responds with marketing language that crosses into drug-claims territory; the FDA's misbranding authority responds in turn. The PCAC track, the shortage-status track, and the Warning Letter track are three separate regulatory mechanisms that have collectively reshaped what is buyable in the GLP-1 category as of May 2026.
Three forward indicators that will move the market further over 2026–2027.
The retatrutide approval timeline. If brand retatrutide receives FDA approval in 2027 (see our TRIUMPH-4 Phase 3 results read), it adds a brand prescription product to the legal channel. It does not open a compounded retatrutide channel — retatrutide is not in the existing shortage category and would not enter compounding eligibility on approval.
The semaglutide / tirzepatide brand-shortage status. If either brand product re-enters confirmed shortage (manufacturing disruptions, demand spikes), the 503A shortage exemption could re-open partially for that compound. The April 2026 PCAC reaffirmation makes a partial re-opening narrower than the 2022–2024 window, but the door is not permanently sealed.
The FDA Warning Letter cadence. The Warning Letter pace through late 2025 and early 2026 was the highest of the cycle. Whether this pace continues, accelerates, or slows is the leading indicator for research-peptide vendor exposure. The FDA Warning Letters database is the place to track this directly.
New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.